Unleashing the Power of Immunotherapy: Kineta’s Revolutionary Anti-CD27 Agonist Preclinical Program to be Showcased at AACR Conference on Tumor Immunology
Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference on Tumor Immunotherapy A New Frontier in Cancer Treatment Seattle-based biotechnology company Kineta, Inc. has announced that it will be presenting its groundbreaking anti-CD27 agonist antibody program at the upcoming American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy. This presentation…